Neurotoxin

Aquavit Files Additional IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis

Retrieved on: 
Saturday, March 18, 2023
Neurotoxin, BA, Drug development, Columbia University Vagelos College of Physicians and Surgeons, University, Hyperhidrosis, Allergan, MBA, Uniform Securities Agent State Law Exam, Doctor of Philosophy, Aquavit, Harvard Medical School, Dermatology, Investment, Patient, Physician, Ophthalmology, FINRA, Axial, Drug discovery, Knowledge, Health, FDA, IND, Clostridium botulinum, Neurology, University of Oxford, Pharmaceutical industry, Management, MD

NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.

Key Points: 
  • NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.
  • Alongside Aquavit's biosimilar program for its botulinum toxin, this will be the first in the world, indicated for palmar hyperhidrosis, approved by FDA.
  • Aquavit has been investing in proprietary delivery technologies and related intellectual property for botulinum toxin.
  • This is a strategic move that puts them ahead of the curve in the fast-growing multi-billion-dollar botulinum toxin market.

Aquavit Files Two IND's For Its Botulinum Toxin With FDA

Retrieved on: 
Friday, March 17, 2023
AB toxin, Neurotoxin, Roa, Hyperhidrosis, Toxicity, Botulinum toxin, Physician, AAD, Knowledge, FDA, IND, Clostridium botulinum, Pharmaceutical industry, Canning, Dermatology, Aquavit

NEW YORK, March 17, 2023 /PRNewswire/ -- Aquavit Holdings, the exclusive licensee of Huons Global's Botulinum Toxin in the USA and Canada, will officially unveil the Aquatox™ program at the Annual American Academy of Dermatology - 2023, the world's largest dermatology conference scheduled from March 17-21, 2023, in New Orleans, LA.

Key Points: 
  • According to The Aesthetic Society and the Global Market Insights, botulinum toxin has been the #1 non-surgical aesthetic procedure since 1999 and is still growing rapidly with only 4 companies with approved botulinum toxin in the US.
  • With a projected CAGR of 7-9%, the global botulinum toxin market in 2026 is expected to be $8.9B.
  • For several years, Aquavit has been investing in its proprietary delivery technologies and related intellectual property for botulinum toxin.
  • We plan to introduce the most innovative botulinum toxin products, uplift and modernize the treatment paradigm" said Sobin Chang, CEO of Aquavit.

SKINCEUTICALS ANNOUNCES OPENING OF SKINCEUTICALS SKINLAB™ IN PARTNERSHIP WITH CAVENDISH CLINIC

Retrieved on: 
Monday, February 27, 2023
Main Street, Skin, Filler (linguistics), US1, Heart, Ageing, Partnership, Skinlab, Consumer, Patient, Neurotoxin, Skin care, Acne, Science, Physician, Pharmaceutical industry, Cosmetics

NEW YORK, Feb. 27, 2023 /PRNewswire/ -- SkinCeuticals, the #1 medical professional skincare brand in the US1, announces the opening of the brand's tenth SkinLab location, SkinCeuticals SkinLab™ by Cavendish Clinic, in the heart of Santa Monica, California. This new location, in partnership with SkinCeuticals UK partner, Cavendish Clinic, and overseen by double board-certified facial plastic surgeon, Dr. Keith Marcus, is the latest addition to the SkinCeuticals SkinLab™ network, joining existing locations including St. Helena, CA; Stamford, CT; Houston, TX; Charleston, SC; Palm Desert, CA; Grand Rapids, MI; Scottsdale, AZ; Miami, FL and New York, NY.

Key Points: 
  • SkinCeuticals and UK based Cavendish Clinic under the direction of Los Angeles Facial Plastic Surgeon, Dr. Keith Marcus, Provide State-of-the-Art Skincare to Consumers in Santa Monica, CA
    NEW YORK, Feb. 27, 2023 /PRNewswire/ -- SkinCeuticals, the #1 medical professional skincare brand in the US1, announces the opening of the brand's tenth SkinLab location, SkinCeuticals SkinLab™ by Cavendish Clinic, in the heart of Santa Monica, California.
  • SkinCeuticals SkinLab™ by Cavendish Clinic is an integrated skincare destination offering advanced, doctor-approved services with the convenience that meets the demands of Santa Monica's client.
  • At SkinCeuticals SkinLab™ by Cavendish Clinic, visitors can look forward to a relaxing, stress-free environment.
  • In partnership with esteemed physicians, SkinCeuticals curated five science-backed signature treatments that deliver professional-grade results with minimal effort and downtime.

Revance to Present New Data on DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia at the Association of Academic Physiatrists Annual Meeting

Retrieved on: 
Thursday, February 23, 2023
Health, FDA, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Obsidian, Medical school, Death, Speech, University of California, Therapy, Headache, Patient, MD, University, Hubli railway division, Pregnancy, MBA, New England Institute of Religious Research, Torticollis, OLS, University of Bonn, ASPEN, Rostov State Medical University, Spasticity, Dysphagia, Neurotoxin, Neurology, AAP, Medication, Food, Poster, Physician, Food and Drug Administration Amendments Act of 2007, Pharmaceutical industry, Online shopping

(RVNC) today announced that new data on DAXXIFY ® will be presented at the annual meeting of Association of Academic Physiatrists (AAP), taking place in Anaheim, California, February 21-24, 2023.

Key Points: 
  • (RVNC) today announced that new data on DAXXIFY ® will be presented at the annual meeting of Association of Academic Physiatrists (AAP), taking place in Anaheim, California, February 21-24, 2023.
  • The supplemental biologics license agreement for DAXXIFY® for the treatment of cervical dystonia is currently under regulatory review with the Food and Drug Administration.
  • The findings reinforce the extended duration of efficacy and favorable safety profile of DAXXIFY®.
  • Dysphagia rates (difficulty swallowing) were low (2.7% for ASPEN-1 and 4.2% for ASPEN-OLS), further supporting DAXXIFY’s safety profile.

Forever Young: Millennials Drive Spending Growth in a Post-COVID Aesthetics Industry

Retrieved on: 
Tuesday, February 21, 2023
Generation Z, Neurotoxin, Growth, Medicine, COVID-19, Patient, Gen, Marketing, Pharmaceutical industry, Aesthetics

NEW YORK, Feb. 21, 2023 /PRNewswire/ -- The Aesthetics industry is undergoing a swift transformation, according to Guidepoint Qsight, the leading market intelligence provider in the Medical Aesthetics industry.

Key Points: 
  • NEW YORK, Feb. 21, 2023 /PRNewswire/ -- The Aesthetics industry is undergoing a swift transformation, according to Guidepoint Qsight, the leading market intelligence provider in the Medical Aesthetics industry.
  • The average sales per Aesthetics practice rose by 34% from 2018 to 2022, with millennials driving that growth.
  • The COVID-19 pandemic brought significant changes to the Aesthetics industry, with more people investing in self-care and wellness.
  • Based on a multi-year analysis of Aesthetics practice sales data across the United States, the average sales per Aesthetics practice rose by 34% from 2018 to 2022, with millennials driving that growth.

Experience the Transformation with Skin Savvy USA Medical Spa, Serving Travis County, Texas

Retrieved on: 
Wednesday, February 15, 2023
Neurotoxin, Lip, BHRT, RN, Patient, Face, Travis County, Texas, Skin, Mouth, Sclerotherapy, Heart, Transgender hormone therapy, Bariatric surgery, Filler (linguistics), Name, Social media, Collection, Beauty salon, Nursing, Cosmetics

When it comes to finding the top-rated, most trusted medical spa, Skin Savvy USA is the ideal choice.

Key Points: 
  • When it comes to finding the top-rated, most trusted medical spa, Skin Savvy USA is the ideal choice.
  • Skin Savvy USA is a premier boutique medical spa and wellness clinic located in the heart of West Lake Hills, Texas.
  • Skin Savvy USA offers a wide range of treatments and services, to help clients across the Travis County, Texas area feel refreshed and confident.
  • Skin Savvy is a full-service medical spa offering full-service body contouring and body sculpting treatments, including TruSculp and Emscuplt.

AS AMERICANS RETURN TO THE OFFICE, AAFPRS UNVEILS AESTHETIC TRENDS FROM ANNUAL FACIAL PLASTIC SURGERY SURVEY

Retrieved on: 
Monday, February 13, 2023
Nose, AAFPRS, Woman, Neurotoxin, Dr. Martens, Australasian Academy of Facial Plastic Surgery, Head, Maintenance, Muscle dysmorphia, Patient, Quarantine, Face, Motivation, News, Gen, Eye, Ageing, Generation Z, Skin, Neck, American Academy of Facial Plastic and Reconstructive Surgery, Intel, Research, Otoplasty, I Am Gen Z, Diabetes, American Academy, Semaglutide, Prevalence, Surgeon, Social media, Weight loss, Body dysmorphic disorder, Dentistry, Cosmetics, Blepharoplasty, Rhinoplasty, MD

WASHINGTON, Feb. 13, 2023 /PRNewswire/ -- The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) , the world's largest association of facial plastic surgeons, today released its 2022 member survey outcomes .

Key Points: 
  • WASHINGTON, Feb. 13, 2023 /PRNewswire/ -- The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) , the world's largest association of facial plastic surgeons, today released its 2022 member survey outcomes .
  • With in-person work, events and socializing moving towards a return to pre-pandemic levels, 2022, like 2021, saw an increase in demand for facial plastic surgery and cosmetic treatments.
  • It is still no surprise that women continue to reign when it comes to undergoing facial plastic surgery.
  • The 2022 AAFPRS annual member survey was conducted in December 2022 by ACUPOLL Precision Research, Inc. through an online survey from a select group of the organization's 2,200 members.

Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, January 9, 2023
Biotechnology, FDA, Pharmaceutical, Health, Speech, Spasticity, Education, Therapy, GAAP, Death, Neuromuscular Disorders, Faculty, Patient, Growth, Food, Hubli railway division, Traction, Investment, Neurotoxin, Dysphagia, Pharmaceutical industry, Video game

Revance Therapeutics, Inc. (RVNC) today provided an update on its early experience program for DAXXIFY® and its preliminary unaudited fourth quarter and full year 2022 financial results.

Key Points: 
  • Revance Therapeutics, Inc. (RVNC) today provided an update on its early experience program for DAXXIFY® and its preliminary unaudited fourth quarter and full year 2022 financial results.
  • Revance expects preliminary unaudited DAXXIFY® revenue from PrevU, its early experience program, to be between $10.5 million and $11.5 million in the fourth quarter 2022, the first quarter of limited commercial availability.
  • Revance expects preliminary unaudited fourth quarter 2022 service revenue from OPUL® and the legacy HintMD fintech platform to be between $2.5 million and $3.5 million and full year 2022 preliminary unaudited service revenue of between $6.5 million and $7.5 million.
  • The company expects to provide its 2023 GAAP and Non-GAAP operating expense guidance in its fourth quarter 2022 earnings announcement.

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Retrieved on: 
Friday, January 6, 2023
Biotechnology, FDA, Pharmaceutical, Health, Prescription Drug User Fee Act, PDUFA, Food, Muscle, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, ASPEN, Injection, Torticollis, Patient, Neuromuscular Disorders, Speech, Physician, Safety, Neurotoxin, FDA, Dysphagia, Spasticity, Hubli railway division, Pharmaceutical industry, MD

Results from the ASPEN-OLS study reinforced the safety findings reported from ASPEN-1 study, as well as the efficacy of DAXXIFY® with up to four repeat treatments.

Key Points: 
  • Results from the ASPEN-OLS study reinforced the safety findings reported from ASPEN-1 study, as well as the efficacy of DAXXIFY® with up to four repeat treatments.
  • “Painful symptom re-emergence is very common for patients with cervical dystonia and up until now physicians have not been able to fully address this issue with existing treatment options,” said Peter McAllister, MD.
  • The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.
  • The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology

Retrieved on: 
Tuesday, December 13, 2022
AEON, Exhibit, Acquisition, BLA, Physician, Sub, Allergan, Neurology, Wardwell, Person, Security (finance), FDA, Reading, Sale, Economics, Prospectus, Latham & Watkins, Neurotoxin, Proxy, Atomic mass, Sumathi Best Television Current Reporting Award, Toxin (comics), History, Sustainability Accounting Standards Board, SPAC, Patient, Therapy, Form, Management, Pharmaceutical industry

Upon closing of the proposed transaction, the combined company will operate as AEON Biopharma, Inc. and is expected to list on Nasdaq under the ticker symbol "AEON".

Key Points: 
  • Upon closing of the proposed transaction, the combined company will operate as AEON Biopharma, Inc. and is expected to list on Nasdaq under the ticker symbol "AEON".
  • AEON has assembled a seasoned team with expertise in neuroscience research, development, regulatory affairs, operations, manufacturing, and commercialization.
  • Marc Forth, CEO and President of AEON Biopharma, said: “We’re making great progress across our late-stage clinical programs as we continue the development of ABP-450 for the treatment of multiple debilitating medical conditions.
  • AEON is a clinical stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets.